These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

582 related items for PubMed ID: 23178916

  • 1. Influence of psoriatic arthritis on the efficacy of adalimumab and on the treatment response of other markers of psoriasis burden: subanalysis of the BELIEVE study.
    Paul C, van de Kerkhof P, Puig L, Unnebrink K, Goldblum O, Thaçi D.
    Eur J Dermatol; 2012; 22(6):762-9. PubMed ID: 23178916
    [Abstract] [Full Text] [Related]

  • 2. Adalimumab for the treatment of moderate to severe psoriasis: subanalysis of effects on scalp and nails in the BELIEVE study.
    Thaçi D, Unnebrink K, Sundaram M, Sood S, Yamaguchi Y.
    J Eur Acad Dermatol Venereol; 2015 Feb; 29(2):353-360. PubMed ID: 24846518
    [Abstract] [Full Text] [Related]

  • 3. Efficacy and safety of adalimumab among patients with moderate to severe psoriasis with co-morbidities: Subanalysis of results from a randomized, double-blind, placebo-controlled, phase III trial.
    Kimball AB, Bensimon AG, Guerin A, Yu AP, Wu EQ, Okun MM, Bao Y, Gupta SR, Mulani PM.
    Am J Clin Dermatol; 2011 Feb 01; 12(1):51-62. PubMed ID: 21110526
    [Abstract] [Full Text] [Related]

  • 4. Adalimumab for nail psoriasis: Efficacy and safety from the first 26 weeks of a phase 3, randomized, placebo-controlled trial.
    Elewski BE, Okun MM, Papp K, Baker CS, Crowley JJ, Guillet G, Sundaram M, Poulin Y, Gu Y, Geng Z, Williams DA, Rich PA.
    J Am Acad Dermatol; 2018 Jan 01; 78(1):90-99.e1. PubMed ID: 28993005
    [Abstract] [Full Text] [Related]

  • 5. Effectiveness of adalimumab in the treatment of scalp and nail affection in patients with moderate to severe plaque psoriasis in routine clinical practice.
    Khobzey K, Liskova I, Szegedi A, Pavlovsky L, Lunder T, Kingo K, Miljković J, Péč J, Bohinc M, Hojnik M.
    Acta Dermatovenerol Alp Pannonica Adriat; 2017 Mar 01; 26(1):11-14. PubMed ID: 28352929
    [Abstract] [Full Text] [Related]

  • 6. Improvement of scalp and nail lesions with ixekizumab in a phase 2 trial in patients with chronic plaque psoriasis.
    Langley RG, Rich P, Menter A, Krueger G, Goldblum O, Dutronc Y, Zhu B, Wei H, Cameron GS, Heffernan MP.
    J Eur Acad Dermatol Venereol; 2015 Sep 01; 29(9):1763-70. PubMed ID: 25693783
    [Abstract] [Full Text] [Related]

  • 7. Nail psoriasis dynamics during biologic treatment and withdrawal in patients with psoriasis who may be at high risk of developing psoriatic arthritis: a post hoc analysis of the VOYAGE 2 randomized trial.
    Tillett W, Egeberg A, Sonkoly E, Gorecki P, Tjärnlund A, Buyze J, Wegner S, McGonagle D.
    Arthritis Res Ther; 2023 Sep 15; 25(1):169. PubMed ID: 37715294
    [Abstract] [Full Text] [Related]

  • 8. Adalimumab for treatment of moderate to severe psoriasis and psoriatic arthritis.
    Bongiorno MR, Pistone G, Doukaki S, Aricò M.
    Dermatol Ther; 2008 Oct 15; 21 Suppl 2():S15-20. PubMed ID: 18837728
    [Abstract] [Full Text] [Related]

  • 9. Relationship of psoriatic arthritis with nail and scalp involvement in Turkish psoriasis patients: Multicentered cross-sectional study.
    Askin O, Engin B, Ozdede A, Kartal SP, Ugurlu S, Akbulut TO, Ekinci AP, Aydogdu İH, Ozden MG, Kok H, Dogan S, Ozturkcan S, Borlu M, Baskan EB, Yilmaz N, Ak T, Topkarci Z, Serdaroglu S.
    Medicine (Baltimore); 2024 Jul 19; 103(29):e38832. PubMed ID: 39029037
    [Abstract] [Full Text] [Related]

  • 10. Long-term treatment of psoriatic patients with adalimumab reduces disease severity and maintains a favorable lipid pattern and a low Atherogenic Index.
    Zangrilli A, Bavetta M, Scaramella M, Bianchi L.
    G Ital Dermatol Venereol; 2018 Apr 19; 153(2):146-154. PubMed ID: 29564871
    [Abstract] [Full Text] [Related]

  • 11. Effectiveness of adalimumab in treating patients with active psoriatic arthritis and predictors of good clinical responses for arthritis, skin and nail lesions.
    Van den Bosch F, Manger B, Goupille P, McHugh N, Rødevand E, Holck P, van Vollenhoven RF, Leirisalo-Repo M, Fitzgerald O, Kron M, Frank M, Kary S, Kupper H.
    Ann Rheum Dis; 2010 Feb 19; 69(2):394-9. PubMed ID: 19815494
    [Abstract] [Full Text] [Related]

  • 12. Efficacy of Guselkumab Compared With Adalimumab and Placebo for Psoriasis in Specific Body Regions: A Secondary Analysis of 2 Randomized Clinical Trials.
    Foley P, Gordon K, Griffiths CEM, Wasfi Y, Randazzo B, Song M, Li S, Shen YK, Blauvelt A.
    JAMA Dermatol; 2018 Jun 01; 154(6):676-683. PubMed ID: 29799960
    [Abstract] [Full Text] [Related]

  • 13. Brodalumab Is Associated with High Rates of Complete Clearance and Quality of Life Improvement: A Subgroup Analysis of Patients with Psoriasis and Concomitant Psoriatic Arthritis.
    Kokolakis G, Vadstrup K, Hansen JB, Carrascosa JM.
    Dermatology; 2022 Jun 01; 238(4):620-629. PubMed ID: 34823247
    [Abstract] [Full Text] [Related]

  • 14. Efficacy of adalimumab across subgroups of patients with moderate-to-severe chronic plaque psoriasis of the hands and/or feet: post hoc analysis of REACH.
    Poulin Y, Crowley JJ, Langley RG, Unnebrink K, Goldblum OM, Valdecantos WC.
    J Eur Acad Dermatol Venereol; 2014 Jul 01; 28(7):882-90. PubMed ID: 23790018
    [Abstract] [Full Text] [Related]

  • 15. Adalimumab improves health-related quality of life in patients with moderate to severe plaque psoriasis compared with the United States general population norms: results from a randomized, controlled Phase III study.
    Revicki DA, Menter A, Feldman S, Kimel M, Harnam N, Willian MK.
    Health Qual Life Outcomes; 2008 Oct 02; 6():75. PubMed ID: 18831744
    [Abstract] [Full Text] [Related]

  • 16. Treatment of psoriasis and psoriatic arthritis.
    Papoutsaki M, Costanzo A.
    BioDrugs; 2013 Jan 02; 27 Suppl 1():3-12. PubMed ID: 23990277
    [Abstract] [Full Text] [Related]

  • 17. Effect of secukinumab on the clinical activity and disease burden of nail psoriasis: 32-week results from the randomized placebo-controlled TRANSFIGURE trial.
    Reich K, Sullivan J, Arenberger P, Mrowietz U, Jazayeri S, Augustin M, Parneix A, Regnault P, You R, Milutinovic M.
    Br J Dermatol; 2019 Nov 02; 181(5):954-966. PubMed ID: 30367462
    [Abstract] [Full Text] [Related]

  • 18. Efficacy of secukinumab and adalimumab in patients with psoriatic arthritis and concomitant moderate-to-severe plaque psoriasis: results from EXCEED, a randomized, double-blind head-to-head monotherapy study.
    Gottlieb AB, Merola JF, Reich K, Behrens F, Nash P, Griffiths CEM, Bao W, Pellet P, Pricop L, McInnes IB.
    Br J Dermatol; 2021 Dec 02; 185(6):1124-1134. PubMed ID: 33913511
    [Abstract] [Full Text] [Related]

  • 19. Treatment of nail psoriasis with TNF-α or IL12/23 inhibitors.
    Jemec GB, Ibler KS.
    J Drugs Dermatol; 2012 Aug 02; 11(8):939-42. PubMed ID: 22859238
    [Abstract] [Full Text] [Related]

  • 20. Safety and efficacy of adalimumab treatment in Japanese patients with psoriasis: Results of SALSA study.
    Asahina A, Torii H, Ohtsuki M, Tokimoto T, Hase H, Tsuchiya T, Shinmura Y, Reyes Servin O, Nakagawa H.
    J Dermatol; 2016 Nov 02; 43(11):1257-1266. PubMed ID: 27129439
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 30.